A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs GSK 356278 (Primary)
- Indications Anxiety disorders; Depression
- Focus Adverse reactions
- Acronyms FTIM
- 17 Sep 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 17 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.